Andrea Lázaro Cebas

Andrea Lázaro Cebas

Auto-generated profile, based on publicly available information

Andrea Lázaro Cebas

Pharmacy Department, Hospital General Universitario Santa Lucía, Cartagena, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJuan Torres Macho
Juan Torres Macho
PRPablo Ryan
Pablo Ryan
jorge valenciajorge valencia
jorge valencia
MPMario Pérez-Butragueño
Mario Pérez-Butragueño
EJEva Jiménez
Eva Jiménez
AMAlejandro Meca
Alejandro Meca
This study aimed to build an easily applicable prognostic model based on routine clinical, radiological, and laboratory data available at admission, to predict mortality in coronavirus 19 disease (COVID-19) hospitalized patients. Methods: We retrospectively collected clinical information from 1968 patients admitted to a hospital. We built a predictive score based on a logistic regression model in which explicative variables were discretized using classification trees that facilitated the identification of the optimal sections in order to predict inpatient mortality in patients admitted with COVID-19. These sections were translated into a score indicating the probability of a patient’s death, thus making the results easy to interpret. Results. Median age was 67 years, 1104 patients (56.4%) were male, and 325 (16.5%) died during hospitalization. Our final model identified nine key features: age, oxygen saturation, smoking, serum creatinine, lymphocytes, hemoglobin, platelets, C-reactive protein, and sodium at admission. The discrimination of the model was excellent in the training, validation, and test samples (AUC: 0.865, 0.808, and 0.883, respectively). We constructed a prognostic scale to determine the probability of death associated with each score. Conclusions: We designed an easily applicable predictive model for early identification of patients at high risk of death due to COVID-19 during hospitalization.

24 May 2017
Verified
Journal Article
Closed access
ALAndrea Lazaro-Cebas
Andrea Lazaro-Cebas
SCSusana Cortijo Cascajares
Susana Cortijo Cascajares
SBSiria Pablos Bravo
Siria Pablos Bravo
MGMaria Del Puy Goyache Goñi
Maria Del Puy Goyache Goñi
GMGema Gonzalez Monterrubio
Gema Gonzalez Monterrubio
JPJose Miguel Ferrari Piquero
Jose Miguel Ferrari Piquero

5 January 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
EIElsa Izquierdo-García
Elsa Izquierdo-García
ALAndrea Lázaro-Cebas
Andrea Lázaro-Cebas
BPBerta Montero Pastor
Berta Montero Pastor
ADAna Such Díaz
Ana Such Díaz
EAELENA ALBA ALVARO ALONSO
ELENA ALBA ALVARO ALONSO
IEIsmael Escobar-Rodríguez
Ismael Escobar-Rodríguez
Background: Hereditary fructose intolerance (HFI) is a rare metabolic disease caused by aldolase B deficiency. The aim of our study was to analyse excipient tolerability in patients with HFI and other related diseases and to design mobile and website health applications to facilitate the search for drugs according to their tolerance.Results: A total of 555 excipients listed in the Spanish Medicines Agency database (July 2023) were classified as suitable for HFI patients, suitable with considerations ((glucose and glucose syrup, intravenous sucrose, oral mannitol, polydextrose, gums and carrageenans, ethanol, sulfite caramel and vanilla), not recommended (intravenous mannitol) and contraindicated (fructose, oral sucrose, invert sugar, sorbitol, maltitol, lactitol, isomaltitol, fruit syrups, honey, sucrose esters and sorbitol esters). Glucose and glucose syrup were classified as suitable with considerations due to its possible fructose content and their potential endogenous fructose production. For other related intolerances, wheat starch was contraindicated and oatmeal was not recommended in celiac disease; oral lactose and lactose-based coprocessed excipient (Cellactose®) were not recommended in lactose intolerance; and glucose, invert sugar and oral sucrose were not recommended in diabetes mellitus. The applications were named IntoMed®. Results are listed in order of tolerability (suitable drugs appear first and contraindicated drugs at the end), and they are accompanied by a note detailing their classified excipients. If a drug contains excipients within different categories, the overall classification will be the most restrictive. The apps are also able to classify substances with the same criteria if they act as active ingredients. The tools exhibited good usability (82.07 ± 13.46 points on the System Usability Scale [range: 0-100]) on a sample of HFI patients, their families and health care professionals.Conclusions: IntoMed® is a tool for finding information about the tolerability of drugs according to excipients for patients with HFI and other related intolerances, with good usability. It is a fast and reliable system that covers the current excipient legislation and expands on it with other specific information: HFI patients should be alert for excipients such as mannitol (especially in intravenous drugs), fruit syrups, honey, sulfite caramel or vanilla. Glucose might contain or produce fructose, and special precaution is needed because of potential errors in their composition.

5 October 2018 in Nutrición Hospitalaria
Verified
Journal Article
Open access
PDF file
ACAndrea Lázaro Cebas
Andrea Lázaro Cebas
SBSiria Pablos Bravo
Siria Pablos Bravo
PMPilar Gomis Muñoz
Pilar Gomis Muñoz
MOMiguel Ángel Orbaneja
Miguel Ángel Orbaneja
SSSamantha Spiers
Samantha Spiers
JPJosé Miguel Ferrari Piquero
José Miguel Ferrari Piquero
Objetivo: conocer si hay precipitación en nutriciones parenterales (NP) con gluconato cálcico y glicerofosfato sódico en las cantidades límites del documento de consenso español de preparación de nutrición parenteral SENPE/SEGHNP/SEFH 2008. Métodos: se prepararon por triplicado siete NP: cinco de 100 ml con concentraciones de aminoácidos, calcio y fósforo similares a las concentraciones máximas de precipitación del documento consenso SENPE/SEGHNP/SEFH y dos controles, uno sin calcio y fósforo y otro con alto contenido de calcio y fósforo y baja concentración de aminoácidos. Las NP no contenían lípidos. Las NP se almacenaron 20 horas a temperatura ambiente y cuatro horas a 35 °C, y se filtraron con un fi ltro de 0,2 micras. Estos fi ltros se transportaron y observaron parcialmente por microscopía electrónica. Los cristales observados se analizaron por espectrometría por dispersión de rayos X a 1.000 aumentos. Al observarse gran cantidad de precipitados, que no se correspondían a los estudios publicados, se realizaron estudios complementarios para conocer su origen. Resultados: en todos los casos, a excepción del control sin calcio y fósforo, se observaron precipitados. Sin embargo, estos cristales, según nuestros estudios, se produjeron después de la fi ltración y en su composición está el calcio, pero no el fósforo. También se observaron partículas provenientes de la preparación de nutrición parenteral. Conclusiones: en nuestro estudio no encontramos precipitados de fosfato cálcico en los límites recogidos en el documento consenso SENPE/SEGHNP/SEFH. Sin embargo, es posible que se formen microprecipitados con calcio en su composición. Es importante fi ltrar las NP previamente a su administración.

1 September 2015 in Clinical Nutrition
Verified
Journal Article
Closed access
SBS. Pablos Bravo
S. Pablos Bravo
ACA. Lázaro Cebas
A. Lázaro Cebas
MZM.á. Valero Zanuy
M.á. Valero Zanuy
JSJ. García Sánchez
J. García Sánchez
PMP. Gomis Muñoz
P. Gomis Muñoz
JPJ.M. Ferrari Piquero
J.M. Ferrari Piquero

1 September 2020 in Journal of Healthcare Quality Research
Verified
Journal Article
Closed access
CEC. Rosas Espinoza
C. Rosas Espinoza
JTJ.M. Caro Teller
J.M. Caro Teller
MLM. Arrieta Loitegui
M. Arrieta Loitegui
ACA. Lázaro Cebas
A. Lázaro Cebas
SPS. Ortiz Pérez
S. Ortiz Pérez
JPJ.M. Ferrari Piquero
J.M. Ferrari Piquero